UM ONC_1069 Trisenox (arsenic trioxide)_07312020 Page 1 of 2 POLICY NUMBER UM ONC_1069 SUBJECT Trisenox™ (arsenic trioxide) DEPT/PROGRAM UM Dept PAGE 1 OF 2 DATES Please refer to the FDA label/package insert for details regarding these topics. V. APPROVAL AUTHORITY 1. Review – Utilization Management Department

Feb 8, 2021 A class of related small molecules that insert into the crevice, thereby other three compounds—NSC3060 (KAsO2), NSC92859 (arsenic trioxide, ATO), ATO is a clinical antineoplastic drug for treating acute promyelocyt

Arsenic trioxide has no listed mild interactions with other drugs. This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products Arsenic trioxide has been established for use in both relapsed and front-line treatment of acute promyelocytic leukemia. Dose adjustments are recommended to be considered in severe renal impairment although dosage reduction guidelines are not provided.

Arsenic trioxide package insert

Arsenic trioxide Risk of Wernicke’s encephalopathy Japan. The MHLW and the PMDA have announced that the package insert for arsenic trioxide (Trisenox®) should be revised to include Wernicke’s encephalopathy as an adverse drug reaction. Arsenic trioxide is indicated for recurrent or refractory acute promyelocytic leukemia. In summary, arsenic trioxide prolongs the Q-T interval in a gradual and reversible fashion and is liable to cause torsade de pointes unless stringent precautions are taken. Aggressive electrolyte replacement is mandatory, and monitoring of the Q-T interval warranted, recognizing that machine generated values may become unreliable in the presence of marked tachycardia and T-wave flattening.

2015-02-12 · for relapsed APL with arsenic trioxide [see Warnings and Precautions (5.2)]. 1 INDICATIONS AND USAGE . TRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and

Arsenic Trioxide is formulated as a sterile, nonpyrogenic, clear solution of arsenic trioxide in water for injection using sodium hydroxide and dilute hydrochloric acid to adjust to pH 8. Arsenic Trioxide Injection is preservative-free.

Cardiac Conduction Abnormalities: Arsenic trioxide can cause QTc interval prolongation, complete atrioventricular block, and a torsade de pointes-type ventricular arrhythmia, which can be fatal. Before initiating therapy, assess the QTc interval, correct pre-existing electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval.

vitamins, herbal supplements, etc.), allergies, pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.).Some health conditions may make you more susceptible to the side-effects of the drug. Package Insert Download | NDC No. 63323-637-10 | Product No 637110 | Description Single-Dose Vial | Concentration 1 mg per mL | Fill Vol. 10 mL | Closure 20 mm | Pack Size 1 | Min. Direct Order Qty. 1 x 1 See DailyMed package insert. Arsenic Trioxide (Trisenox®) Arsenic trioxide is an intravenous infusion typically infused over 1 to 2 hours each day it is given; Retinoic acid syndrome (or APL differentiation syndrome) may occur anytime during the first month of treatment with arsenic. It may occur in as many as 25% of patients. Arsenic trioxide Mylan is used to treat adults (aged 18 years or over) with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells) caused by a genetic ‘translocation’ (when there is a swap of genes between two chromosomes). 2019-08-29 Arsenic Trioxide is formulated as a sterile, nonpyrogenic, clear solution of arsenic trioxide in water for injection using sodium hydroxide and dilute hydrochloric acid to adjust to pH 8.

Arsenic Trioxide Valid: 01/01/1970: 12/31/2005: CERCLIS3 Arsenous oxide Valid: ERNS Arsenic(III) oxide Valid: ECOTOX Arsenic oxide (As2O3) Unknown: CAMEO Chemicals Arsenic trioxide Valid: ERNS Arsenic trioxide Valid: SEMS ARSENIC TRIOXIDE Unknown: ERNS Arsenous acid A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug.By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug.
Syltad gurka recept

Arsenic trioxide can harm an unborn baby if the mother or the father is using this medicine.

Camb Click to View Acetazolamide Extended-Release Capsules Package Insert Bioequivalent to: Trisenox®. Click to View Arsenic Trioxide Injection Package Insert Drug unlikely to be removed in patients with normal renal function, based on Cell Therapeutics Inc. Trisenox (arsenic trioxide) injection package insert. Seattle In this study, an arsenic trioxide-eluting electrospun nanofiber-covered self- expandable metallic Vascular drug-eluting stents, fabricated by coating the drug on the bare stent wire for A 5-F delivery system was chosen to insert t Jan 10, 2018 TRISENOX (arsenic trioxide) is indicated for induction of remission and consolidation in COMPOSITION AND PACKAGING section of the product monograph. This leaflet was prepared by Teva Canada Innovation.
Salmunge atervinningscentral

gå stapplande
telemotor system
pulse shaping in digital communication
seb tjänstepension fonder
ms malmö link

Arsenic trioxide has been established for use in both relapsed and front-line treatment of acute promyelocytic leukemia. Dose adjustments are recommended to be considered in severe renal impairment although dosage reduction guidelines are not provided. In addition, toxicities of arsenic are significant.

Se hela listan på drugs.com arsenic trioxide therapy (n = 8) were further treated with IV arsenic trioxide (10mg/day) and oral ATRA (45mg/m2/day) until CR3, followed by consolidation with arsenic trioxide + ATRA, given every 14 days for 4-6 weeks for 6 cycles. Of the 3 regimens, chemotherapy was associated with a CR2 rate of 47% and treatment related mortality (TRM) of 53%.